# Feasibility of [11C]Acetate-PET in LAM and TSC

> **NCT05467397** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 7 (actual)

## Conditions studied

- Lymphangioleiomyomatosis
- Tuberous Sclerosis Complex

## Interventions

- **DRUG:** [11C]acetate

## Key facts

- **NCT ID:** NCT05467397
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-30
- **Primary completion:** 2024-06-04
- **Final completion:** 2026-06-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467397, "Feasibility of [11C]Acetate-PET in LAM and TSC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05467397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*